Vir Biotechnology, Inc. (VIR) analyst actions
Rating and price-target actions on VIR in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the VIR overview →
3 measured VIR analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta | Press release | -0.30% | +0.59% | |
| Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta | Press release | -1.34% | -3.06% | |
| Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program | Press release | -1.06% | -2.26% |
Keep exploring
More VIR: earnings → · SEC filings → · VIR overview →